Healthcare stocks remain popular during the latest bout of selling pressure within the broader markets. Despite potential drug-price controls, investors are seeing a number of strong drug pipelines and promising clinical trials. The Frost & Sullivan Healthcare and Life Sciences experts are predicting big disruptions, transformations and innovations in the coming years as the healthcare industry continues to overhaul outmoded business models. “Our interactive workshop is designed to help managers and CEOs understand key issues affecting the healthcare industry globally,” noted Sandeep Sinha, Vice President & Head, Healthcare and Life Sciences, Frost & Sullivan. “Advances in areas ranging from cancer immunotherapy products to blood testing, as well as the convergence of cutting-edge technology such as artificial intelligence and blockchain will help shape the healthcare industry into a much-anticipated, value-based care paradigm.” Healthcare stocks remain in focus this week after the stock market posted its worst Black Friday session last week. The Select Sector SPDR Healthcare ETF (XLV) has climbed from lows of $88.98 on Friday to as high as $90.75 Monday as the market pushed higher, led by healthcare stocks. Click Here For 4 Healthcare Stocks Moving On Recent News